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Abstract 
A relevant mode of resistance to antiangiogenic and radiotherapy appears to be promotion of 
tumour cell motility and invasiveness in various cancer types, a process commonly referred 
to as ‘evasive resistance’ that may underlie progressive disease and complicates further 
treatment. Hence, a logical advancement in current oncology consists in optimizing 
antiangiogenic regimens by identifying suitable complementary strategies, ideally targeting 
cell motility. Here we report that clinically relevant radiation-enhanced inhibition of the mTOR 
complexes 1 and 2 exercises such a dual control of angiogenesis and invasiveness 
independent from PTEN/AKT activation in glioblastoma, a tumour entity that is paradigmatic 
for both excessive vascular proliferation and cell invasion. This is due to a concerted 
disrupture of the VEGF/VEGFR-2 signalling axis and likewise suppression of RGS4, which 
we identified to be a key driver of glioblastoma invasiveness. This combined 
antiangiogenic/antiinvasive approach might be a promising therapeutic option and warrants 
further clinical investigation in upfront glioblastoma therapy. 
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Introduction 
Antiangiogenic treatment has become an integral part of modern cancer therapy, targeting 
the vasculature of numerous aggressive malignancies including glioblastoma (Kerbel and 
Folkman, 2002; Norden et al., 2008a). This tumour entity is paradigmatic for and clinically 
determined by profoundly increased pathological angiogenesis and invasive growth (Louis, 
2006). Although angiogenesis inhibitors targeting the vascular endothelial growth factor 
(VEGF) signalling pathway are efficacious, a growing body of evidence suggests that, after 
an initial response with vascular dropout and tumour stasis, pharmacologically impaired 
angiogenesis can eventually act as a detrimental driving force for enhanced tumour cell 
invasion into surrounding tissue, a process commonly referred to as ‘evasive resistance’ 
(Casanovas et al., 2005; Paez-Ribes et al., 2009). In clinical series, upon progression on 
antiangiogenic therapy with the VEGF-directed antibody bevacizumab, glioblastomas may 
display a more infiltrative pattern of recurrence (Norden et al., 2008b). To overcome this 
often insidious consequence and optimize antiangiogenic therapies, it is a major challenge 
integrating antiangiogenic with antiinvasive mechanisms into one combined treatment 
concept. 
Serving as a central signalling hub integrating multiple intra- and extracellular cues, the 289-
kDa serine/threonine kinase mammalian target of rapamycin (mTOR) is an attractive 
anticancer target. The current understanding of mTOR is that it nucleates at least two multi-
protein complexes, mTORC1 and mTORC2, that direct cell metabolism, growth, proliferation, 
survival, and tumour angiogenesis. The rapamycin-sensitive mTORC1 essentially mediates 
phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT/PKB) signals and, through its direct 
phosphorylation of the ribosomal protein S6 kinase 1 (S6K1) and the eukaryotic translation 
initiation factor 4E (eIF4E) binding protein 1 (4E-BP1), promotes many anabolic processes, 
including biosynthesis of proteins, lipids and organelles, and limits catabolic processes such 
as autophagy (Guertin and Sabatini, 2007; Laplante and Sabatini, 2009). Signalling through 
mTORC2 is less well understood, but the S473 phosphorylation on the AKT kinase by 
mTORC2 implicates mTOR in acting both upstream and downstream of AKT (Sarbassov et 
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al., 2005). mTORC2 is involved in cytoskeletal organization (Jacinto et al., 2004) and might 
thus regulate cancer cell motility, migration and invasion. 
Activation of the signalling network engaged by the PI3K/AKT/mTOR axis frequently occurs 
by activation of receptor tyrosine kinases (RTK), e.g., the epidermal growth factor receptor 
(EGFR) being the most commonly altered RTK in glioblastoma, or in 30% to 40% of 
glioblastomas by mutations/deletions in the phosphatase and tensin homolog deleted on 
chromosome 10 (PTEN) tumour suppressor gene (Cancer Genome Atlas Research Network, 
2008).  
Preclinical models have suggested enhanced antitumoural activity of mTOR inhibition in 
PTEN-deficient tumours (Neshat et al., 2001; Podsypanina et al., 2001) and translational 
studies have revealed that activation of the PI3K/AKT/mTOR pathway is associated with 
reduced survival of glioma patients (Chakravarti et al., 2004). Consequently, this signalling 
pathway has been subjected to a number of single- or multi-targeted therapies including the 
mTOR inhibitor rapamycin or its derivatives, the ‘rapalogs’ everolimus (RAD001), deforolimus 
(AP23573), and temsirolimus (CCI-779) (Faivre et al., 2006). However, in relapsed 
glioblastoma, targeting the EGFR/PI3K/AKT/mTOR signalling pathway failed to demonstrate 
convincing clinical activity, neither for mTOR inhibition alone nor in combination with EGFR 
inhibition (Galanis et al., 2005; Doherty et al., 2006; Kreisl et al., 2009; Reardon et al., 2010). 
As with alkylating agents which are of limited value at recurrence but improved first-line 
treatment in glioblastoma when combined with radiotherapy (Stupp et al., 2009), mTOR 
inhibition may be an option for newly diagnosed, i.e., treatment-naïve glioblastomas that 
likely lack some of the mechanisms of resistance met at recurrence. CCI-779 (Torisel®) has 
been approved for advanced renal cell carcinoma (Motzer et al., 2007) and relapsed or 
refractory mantle cell lymphoma (Hess et al., 2009). Cytostatic effects of CCI-779 on tumour 
cells (Geoerger et al., 2001; Dudkin et al., 2001) could complement the genotoxic activity of 
radiation therapy in upfront treatment of glioblastoma. mTOR inhibition could additionally 
counteract two key adverse side effects of radiation therapy promoting tumour recurrence: 
induction of angiogenesis and invasiveness (Wild-Bode et al., 2001; Colevas et al., 2003; 
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Abdollahi et al., 2003). Conclusively, the rationale of the present study was to test mTOR 
inhibition for anti-glioma effects when combined with ionizing radiation, for its potential to 
optimize antiangiogenesis through concomitant suppression of cell invasion, and to analyze 
putative underlying mechanisms of action. 
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Material and methods 
Cell culture, reagents and transfections 
The human malignant glioma cell lines LN-308, LN-229, LN-428 and LN-18 were provided by 
N. de Tribolet (Lausanne, Switzerland). Importantly, LN-229 cells still harbour the wild-type 
TP53 gene and were therefore renamed LNT-229 (T for Tuebingen) for clarification. U87MG 
and T98G glioma cells were purchased from the American Type Culture Collection 
(Manassas, VA, USA). The murine glioma cell line SMA-560 was provided by D.D. Bigner 
(Durham, NC, USA). Glioma cells were maintained at standard conditions (Weiler et al., 
2006). Glioblastoma-initiating cell (GIC) cultures T269 and T325 were grown as previously 
described (Svendsen et al., 1998) using minor modifications (Rieger et al., 2008). Primary 
human umbilical vein endothelial cells (HUVEC) were purchased from PromoCell 
(Heidelberg, Germany). Human cerebral microvascular endothelial cells (hCMEC/D3) were 
provided by Pierre-Olivier Couraud (Institut Cochin, Université René Descartes, Paris, 
France). HUVEC and hCMEC/D3 were cultured as described previously (Berger et al., 
2010). CCI-779 was provided by Wyeth Pharma GmbH (Muenster, Germany) and dissolved 
in dimethyl sulfoxide (DMSO). The PKC- inhibitor enzastaurin (LY317615) was purchased 
from Selleck Chemicals LLC (Houston, TX, USA) and dissolved in DMSO. Cells were 
irradiated in a GE Healthcare Buchler (Braunschweig, Germany) radiation device OB58 
using a caesium-137 source. 
The ON-TARGET-plus SMART-pool siRNA by Dharmacon RNA Technologies (Lafayette, 
CO, USA) was used to knock down RGS4 (NM_005613; Smartpool No. L-009900), Rictor 
(NM_152756; Smartpool No. L-016984) and Raptor (NM_020761; Smartpool No. L-004107). 
ON-TARGET-plus siControl Nontargeting Pool (D-001810-10-05, Dharmacon) and a 
transfection without siRNA were used as negative controls. Stable overexpression of RGS4 
in LN-308 glioma cells was achieved by transfecting the pCR3.0 eukaryotic expression 
vector (Invitrogen, Karlsruhe, Germany) harbouring RGS4-encoding cDNA (pCR3.0-RGS4; a 
gift from Thomas Wieland, University of Heidelberg, Mannheim, Germany) using Fugene HD 
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Transfection Reagent (Roche, Mannheim, Germany) and selection with G418 (Sigma-
Aldrich, Taufkirchen, Germany). pCR3.0 served as an empty vector control. 
 
cRNA microarray analysis 
For gene expression analyses, LN-308 glioma cells treated with CCI-779 at 10 nmol/L or 
DMSO as a vehicle control for 48 h were irradiated at 4 Gy or not and exposed, for another 
48 h, to continued treatment with CCI-779 and DMSO, respectively. Total RNA was extracted 
using the RNeasy Kit (Qiagen, Hilden, Germany). RNA integrity was assessed with a 2100 
Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). Only samples with an RNA 
integrity number (RIN) above seven were used for further processing. Sample labelling with 
the Low RNA Input Linear Amplification Kit and hybridization on 4 x 44K Whole Human 
Genome Microarrays (Agilent) were performed according to the manufacturer´s protocol. In 
brief, one µg of total RNA was subjected to reverse transcription and subsequent cRNA 
synthesis and labelling with Cy3- or Cy5-CTP, respectively. Samples were hybridized against 
universal human reference RNA (Agilent), dye swap experiments were included. Data 
processing was performed using ChipYard (http://www.dkfz.de/genetics/ChipYard/), an in-
house developed R-based platform. Normalized data was further analyzed using the open 
source platform Chipster (http://chipster.sourceforge.net/). Differentially expressed genes 
were identified using the implemented empirical Bayes method (Smyth, 2004) with 
adjustment for multiple testing according to Benjamini-Hochberg and a significance threshold 
of p < 0.05. Array data have been deposited in NCBI’s Gene Expression Omnibus (GEO) 
(Edgar et al., 2002) and are accessible through GEO  
Series accession number GSE24232 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=G
SE24232) 
 
Quantitative reverse transcription polymerase chain reaction 
Quantitative reverse transcription polymerase chain reaction (qRT-PCR) was done as 
described (Opitz et al., 2009). RGS4 expression results were normalized to glyceraldehyde-
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3-phosphate dehydrogenase (GAPDH). Expression of Raptor and Rictor was normalized to 
the eukaryotic translation elongation factor 1 (eEF1). Primer sequences are given in 
Supplementary Table 1. 
 
Immunoblot 
Preparation of cell lysates and immunoblots were performed as described (Weiler et al., 
2006). Antibodies are given in Supplementary Table 2. 
 
Flow cytometry 
All flow cytometry work was carried out on a BD FACSCanto II flow cytometer (BD 
Biosciences, Heidelberg, Germany), and results were analyzed using FACSDiva 6.1 
software (BD Biosciences). Antibodies are listed in Supplementary Table 2. 
 
Assessment of PTEN status 
Sequence analysis of PTEN-specific cDNAs was done in comparison with the respective 
database entries for human or murine PTEN mRNAs. Sequence primers are listed in 
Supplementary Table 1. Immunoblot analysis of PTEN levels and AKT phosphorylation at 
T308 and S473 was carried out as described (Weiler et al., 2006). PTEN-specific 
immunohistochemistry was performed on 3 µm sections from paraffin-embedded patient 
tumour tissue with endothelial cells as an internal positive control for PTEN positivity. 
Antibodies are listed in Supplementary Table 2. Methylation-specific PCR was used to 
analyze the PTEN promoter region for potential methylation-mediated epigenetic silencing 
using one microgram of genomic DNA treated with sodium bisulfite using the Qiagen EpiTect 
Kit (Qiagen). Primers listed in Supplementary Table 1. 
 
Clonogenicity and GIC sphere formation assays 
Clonogenic capacity was assessed by seeding glioma cells suspended in culture media and 
counting of macroscopically visible colonies at 96 h. Sphere formation capacity of GIC was 
  Weiler et al.  
  9
determined by seeding dissociated cells derived from sphere-forming GIC cultures at 100 
cells/well in a 96-well plate. CCI-779 or DMSO were added as indicated and refreshed every 
48 h, as well as the GIC growth factors bFGF and EGF (20 ng/mL each). In some 
experiments, GIC were irradiated at 8 Gy 24 h after seeding. Number and size of 
microscopically visible spheres were determined after 14 days in culture. 
 
Cell viability assays 
Glioma cells were stained with trypan blue (Invitrogen) and counted automatically using a 
Beckman Coulter Vi-Cell XR cell viability analyzer (Krefeld, Germany). Crystal violet 
stainings were performed as described (Weiler et al., 2006). 
 
Measurement of VEGF concentrations 
VEGF concentrations in cell culture supernatants of LN-308 glioma cells were quantified 
using the enzyme-linked immunosorbent assay (ELISA) Quantikine kit from R&D Systems 
(Minneapolis, MN, USA). 
 
In vitro angiogenesis assays 
Viability assays using both primary HUVEC and brain-derived hCMEC/D3 and spheroid 
formation and sprouting of HUVEC were performed as described (Berger et al., 2010). 
 
In vitro invasion assays 
Invasion of glioma cells in vitro after indicated pretreatments was assessed in Boyden 
chamber assays (BD Biosciences) as described. Multicellular glioma spheroids of glioma cell 
lines were obtained and evaluated as described (Weiler et al., 2006). 
 
Animal experiments and histology 
All animal work was approved by the governmental authorities (Karlsruhe, Germany) and in 
accordance with the NIH ‘Guide for the Care and Use of Laboratory Animals’. 
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a) Orthotopic xenograft mouse model. One x 105 LN-308 glioma cells stably transfected with 
pCR3.0 or pCR3.0-RGS4 were stereotactically implanted into the right striatum of CD1 nu/nu 
mouse brains (Charles River Laboratories, Sulzfeld, Germany) at a depth of 3 mm with n = 4 
mice in each group. Tumour volume was assessed on day 48 after tumour cell inoculation by 
magnetic resonance imaging (MRI) using a transversal T2-weighted turbo-spin echo 
sequence (see below). Histological analysis was conducted in all animals the same day by 
staining coronally cryosectioned brains (8 µm) with hematoxylin/eosin. 
b) Orthotopic syngeneic mouse model. Five x 103 murine SMA-560 glioma cells were 
implanted as in a) into the brains of 56 six week old VM/Dk mice (inhouse breeding facility, 
German Cancer Research Center, Heidelberg, Germany). Animals were divided into four 
experimental treatment groups (each n = 14; n = 3 for MRI/histology and n = 11 for survival 
analysis according to the Kaplan-Meier method): (i) Control group: daily intraperiteonal (i.p.) 
injections of vehicle substance (sodium chloride 9 g/L solution containing 12% (v/v) ethanol) 
from postoperative day 3 to 17. (ii) Radiation group: one-time cranial irradiation (6 Gy) on 
postoperative day 5 and injections as in (i). (iii) CCI-779 group: daily i.p. injections of CCI-779 
(Torisel®) at 20 mg/kg body weight from postoperative day 3 to 17. (iv) Radiochemotherapy 
group: one-time cranial irradiation (6 Gy) on postoperative day 5 and daily i.p. injections of 
CCI-779 as in (iii). Tumour volumes were assessed in three mice per treatment group on day 
17 after tumour cell inoculation by MRI. For the histological assessment of tumour growth, 
these same mice were sacrificed on postoperative day 20, brains were isolated and 
cryosectioned (8 µm) for further histological analysis. Eleven mice per group were used for 
survival analysis according to the Kaplan-Meier method. Mice were sacrificed by an 
overdose of anaesthetic at the onset of grade 2 neurological symptoms. Neurological 
symptoms were assessed daily according to modified neurological scores (grade 0: normal; 
grade 1: tail weakness or tail paralysis; grade 2: hind leg paraparesis or hemiparesis; grade 
3: hind leg paralysis or hemiparalysis; grade 4: tetraplegia, moribund stage or death). 
c) Cranial irradiation. For local irradiation, brains of VM/Dk mice were irradiated at 6 Gy using 
15 MeV electrons from a standard linac radiation source (Siemens, Munich, Germany). 
  Weiler et al.  
  11
d) Magnetic resonance imaging (MRI). MRI was performed using a 1.5 tesla whole-body MR 
scanner (Siemens Symphony, Munich, Germany) in combination with a custom-made radio-
frequency coil for excitation and signal reception. Morphologic MR imaging was performed 
using a transversal T2-weighted turbo-spin echo sequence (repetition time, TR = 4,000 ms; 
echo time, TE = 109 ms; field of view, FOV = 40 x 40 mm2; matrix = 128, slice thickness = 
1.0 mm; voxel size = 0.3 x 0.3 x 1.0 mm3). The paramagnetic contrast agent gadolinium-
dieethylenetriaminepentaacetic acid (Gd-DTPA, Magnevist®, Bayer-Schering, Berlin, 
Germany) was injected at 100 µl (0.1 mmol per kg body weight) into the mouse-tail vein. 
Intratumoural contrast kinetics were recorded using a T1-weighted inversion-recovery Turbo 
FLASH (IRTF) sequence (TR = 13 ms; TE = 5.3 ms; TI = 300 ms; FOV = 60  x 60 mm2; 
matrix = 128; slice thickness = 2 mm). In total, 80 dynamic scans were acquired from two 
sections within 10.24 min. 
e) Histology. Brains cryosectioned coronally were H&E-stained to visualize tumour and 
healthy brain tissue. Immunohistochemistries were performed as indicated. Antibodies and 
stainings are listed in a table below. For blood vessel quantification, at least five microscopic 
images (Nikon Eclipse 90i upright automated microscope; Nikon, Duesseldorf, Germany) per 
tumour were taken and fluorescent vessels were automatically counted by the NIH ImageJ 
software. 
 
Statistical analysis 
Quantitative in vitro data are expressed as mean ± standard deviation (SD), as indicated. All 
in vitro experiments reported here represent at least three independent replications 
performed in triplicate. Statistical significance was assessed by two-sided Student’s t-Test 
(Excel, Microsoft, Seattle, WA, USA). Values of p < 0.05 were considered significant and 
asterisked. Survival data were plotted by the Kaplan-Meier method and analyzed by the log-
rank test. A two-sided Fisher-Yates test was applied to correlate the PTEN status and AKT 
activation status with the IC50 of CCI-779 in different glioma cell lines. 
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Results 
CCI-779 inhibits glioma growth and prolongs survival in a syngeneic mouse glioma 
model 
In order to investigate whether clinically relevant doses of CCI-779 are efficacious in an 
immunocompetent mouse model, we tested irradiation-combined CCI-779 (CCI-779/RT) at 
20 mg/kg. Clinically relevant doses range from 25 to 75 mg per week flat dosing which 
corresponds, in a normally proportioned male (180 cm, 75 kg), to 4.2 to 33 mg/kg mouse 
weight (www.accessdata.fda.gov/scripts/cder/onctools/animalquery.cfm). Hence, this 
experimental setting allows challenging responsiveness to CCI-779 facing realistic in vivo 
conditions. For this purpose, we used the highly tumourigenic PTEN wild-type spontaneous 
murine astrocytoma (SMA) cell line SMA-560 derived from inbred VM/Dk mice (Sampson et 
al., 1997). We confirmed its responsiveness to mTOR inhibition by demonstrating 
dephosphorylation of murine RPS6 in response to CCI-779 (Fig. 1A). Following orthotopic 
implantation of these cells into VM/Dk mice, we monitored glioma growth by cranial MRI (Fig. 
1B, top row) and compared the combined treatment regimen of CCI-779 (daily doses of 20 
mg/kg body weight, days 3 to 17) and single fraction cranial irradiation (RT; 6 Gy, day 5) with 
either treatment alone, CCI-779 or RT, and a vehicle treatment for CCI-779. Tissue analyses 
on day 20 after surgery largely confirmed the MRI-based observations (Fig. 1B, middle row) 
and revealed inhibition of mTOR signalling in vivo as indicated by abrogated phosphorylation 
of ribosomal protein S6 (RPS6), a direct substrate of mTORC1-phosphorylated S6K1 that 
correlates with mTORC1 activity (Park et al., 2002) within the tumour tissues of all CCI-779-
treated animals (Fig. 1B, bottom row). Median neurological symptom-free survival of SMA-
560 glioma-bearing mice that had received CCI-779 or CCI-779/RT was significantly 
increased by 35% and 50%, respectively. Most importantly, CCI-779/RT produced a 
significant survival advantage over RT or CCI-779 alone. Despite considerable differences 
on MRI and histology at defined points of time, discontinuation of CCI-779 after 15 days 
allowed the tumours to relapse (Fig. 1C). 
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Inhibition of glioma cell growth by irradiation-enhanced mTOR inhibition 
We investigated chronic effects of ionizing radiation-combined mTOR inhibition with CCI-779 
to mimic the clinical situation where tumours are perpetually exposed to treatment for a 
longer period of time, and established effective CCI-779 concentrations in several glioma cell 
lines. Phosphorylation of ribosomal protein S6 (RPS6), a direct substrate of mTORC1-
phosphorylated S6K1 that correlates with mTORC1 activity (Park et al., 2002) was inhibited 
by CCI-779 in a concentration-dependent manner (Fig. 2A). Of note, ionizing radiation did 
not additionally influence the extent of RPS6 phosphorylation (Supplementary Fig. 1A). 
mTOR inhibition induced a G1 cell cycle arrest in PTEN-deficient LN-308 glioma cells. 
However, when used as a radiosensitizer, it did not affect the G1/S transition but enhanced 
the G2 cell cycle arrest caused by irradiation (Fig. 2B). Further, it enhanced the 
anticlonogenic effect of irradiation (Fig. 2C). The sphere-forming capacity of PTEN-deficient 
primary glioblastoma-initiating cells (GIC) was likewise impaired by the combined treatment 
(Fig. 2D). Similarly, the autophagy-inducing effect of ionizing radiation was enhanced when 
combined with CCI-779 (Fig. 2E), yet without enhancing irradiation-induced apoptosis to a 
significant extent (Supplementary Fig. 1B). In summary, mTOR inhibition and ionizing 
radiation exert promising cytostatic anti-glioma effects. 
 
The PTEN status is not sufficient to predict growth suppression by mTOR inhibition 
Next, we correlated the PTEN status of both glioma cell lines and primary GIC cultures 
(Table 1 and Supplementary Fig. 2A-C) with cell type-specific IC50 values of CCI-779 (Table 
1 and Supplementary Fig. 2D). Neither PTEN mRNA expression nor protein levels, PTEN 
promoter methylation, PTEN mutational status nor constitutive AKT phosphorylation at T308 
or S473 correlated with the response to CCI-779 suggesting that PTEN is only of limited value 
in predicting the sensitivity of glioma cells to mTOR inhibition with CCI-779. 
 
Irradiation-enhanced mTOR inhibition exerts combined antiangiogenic and 
antiinvasive activity  
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Rapamycin and its analogs are suppressors of angiogenesis in several cancer types, mainly 
by inhibiting the release of tumour cell-derived VEGF (Guba et al., 2008). Hence, we tested 
whether CCI-779 reverses the release of hypoxia-inducible factor (HIF)-1-driven VEGF that 
becomes increased in response to ionizing radiation and hypoxia (Lund et al., 2004; 
Tabatabai et al., 2006). Inhibition of mTOR markedly suppressed HIF-1 production induced 
by irradiation or sublethal hypoxia and reduced VEGF levels (Fig. 3A,B). Moreover, alone 
and combined with irradiation, it demonstrated strong activity in viability assays of primary 
HUVEC and brain-derived hCMEC/D3 (Fig. 3C,D). Furthermore, mTOR inhibition alone also 
reduced VEGF-induced sprouting of HUVEC used as a further independent endothelial cell 
assay and surrogate for angiogenesis (Fig. 3E). Conclusively, in glioblastoma, mTOR 
inhibition counteracts the proangiogenic cues elicited by ionizing radiation and tumour 
hypoxia.  
In addition, mTOR inhibition caused a 50-70% reduction in glioma cell invasiveness 
irrespective of the PTEN status (Fig. 4A). Further, when combined with irradiation, mTOR 
inhibition reversed the proinvasive effect of sublethal irradiation on LNT-229 glioma cells in a 
supra-additive way (Fig. 4B). Consistent with the results obtained in the matrigel invasion 
assays, the combined treatment regimen enhanced the antiinvasive effect of a single 
treatment with CCI-779 in a model of multicellular spheroids (Fig. 4C). Notably, this effect 
was even more pronounced in GIC (Fig. 4D). 
 
VEGFR-2 is induced by ionizing radiation and counter-regulated by mTOR inhibition 
on human endothelial cells 
To gain more insight into the molecular mechanisms underlying the combined antiangiogenic 
and antiinvasive modes of action of CCI-779 in glioma cells, we performed comparative 
cRNA microarray analyses and assessed the transcript expression profiles of LN-308 cells 
following treatment with CCI-779, radiation or both. CCI-779 upregulated 64 and 
downregulated 91 transcripts. Combined treatment resulted in upregulation of 85 transcripts 
and downregulation of 65 transcripts. The CCI-779 and combined treatment groups showed 
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an overall overlap of 58 deregulated transcripts. Validation by quantitative reverse 
transcription polymerase chain reaction (qRT-PCR) determined VEGFR-2 as the most 
promising candidate to explain the antiangiogenic actions of mTOR inhibition in glioblastoma. 
VEGFR-2 was downregulated by CCI-779 in LN-308 glioma cells in comparative cRNA 
microarray analyses irrespective of irradiation (Fig. 5A). Immunoblot analyses of VEGFR-2 
expression on glioma cell lines with differing PTEN backgrounds suggested that PTEN-
mutant glioma cells were more sensitive towards CCI-779-mediated downregulation of 
VEGFR-2 (Fig. 5B). Unlike glioma cells, human endothelial cells upregulated VEGFR-2 
mRNA and protein expression in response to irradiation. This induction was counteracted by 
CCI-779 in a concentration-dependent manner (Fig. 5C).  
 
RGS4 acts as a potent driver of human glioma cell invasiveness 
Checking our cRNA microarray analyses data for candidates associated with cell motility, we 
found regulator of G-protein signalling 4 (RGS4) attractive for further evaluation. We 
confirmed down-regulation of RGS4 in LN-308 glioma cells in response to treatment with 
CCI-779 irrespective of irradiation (Fig. 6A). Notably, in PTEN-mutant glioma cells, a CCI-
779 concentration of 10 nmol/L was sufficient to abrogate RGS4 expression whereas in 
PTEN wild-type cells 1-10 µmol/L was necessary to achieve an equipotent effect suggesting 
that the protective effect of a PTEN wild-type status can be overcome in a concentration-
dependent manner (Fig. 6B). Of note, these concentrations can be achieved in the clinic as 
the peak concentration of CCI-779 following an intravenous infusion of just 25 mg reaches 
500 nmol/L. Silencing of RGS4 in LN-308 cells resulted in an 80% decrease in invasion. 
Conversely, stable overexpression of RGS4 in the same cell line lead to a 62% augmentation 
in invasion (Fig. 6C). Treatment of RGS4-overexpressing LN-308 cells with CCI-779 reduced 
expression of RGS4 and invasiveness of RGS4-overexpressing cells (Fig. 5C), proving that 
the antiinvasive effect of CCI-779 treatment was specifically mediated through impaired 
RGS4 signalling. On day 48 after intracerebral implantation of LN-308 glioma cells 
constitutively overexpressing the RGS4 protein (Fig. 6D) without influencing cell viability (Fig. 
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6E), T2-weighted MRI scans demonstrated a five-fold increased mean volume of lesions with 
RGS4-overexpressing gliomas compared with empty vector-transfected LN-308 control 
tumours (Fig. 6F). Upon histological examination, RGS4-overexpressing gliomas showed 
markedly increased satellite formation compared with otherwise non-invasively growing LN-
308 gliomas as observed under control conditions (Fig. 6G). 
 
The feedback activation of AKT is abolished by inhibition of mTORC2 
Rapalog-based inhibition of mTOR activates AKT by phosphorylation while suppressing 
mTORC1 signalling (O’Reilly et al., 2006), and AKT activation during mTOR inhibition is 
tightly associated with development of cellular resistance towards mTOR inhibitors. We 
wanted to clarify whether CCI-779 treatment would result in AKT activation and thus possibly 
confer resistance of glioma cells to CCI-779. CCI-779 applied at 10 nmol/L inhibited 
mTORC1 activity as assessed by decreased phosphorylation of RPS6, but did not alter 
mTORC2 activity, as indicated by unaltered levels of phospho-mTORS2481, a recently 
described pharmacodynamic biomarker for intact mTORC2 (Copp et al., 2009). This was 
paralleled by an increase in phosphorylation of AKTS473. However, 10 µmol/L CCl-779 
disrupted mTORC2 activity and reduced AKTS473 phosphorylation back to baseline 
suggesting that feedback activation of AKT during mTORC1 inhibition at low concentrations 
was mediated by mTORC2 kinase activity (Fig. 7A). 
 
CCI-779-mediated suppression of angiogenesis and invasiveness is regulated through 
both mTORC1 and mTORC2 
Next, we wanted to know whether regulation of VEGFR-2 and RGS4 was mediated through 
signalling of mTORC1, mTORC2, or both. We approached this issue using siRNA-mediated 
knock-down transfectants of LN-308 cells targeting the mRNAs of two interacting proteins, 
mTOR specifically assembles with to form either mTORC1 or mTORC2: Raptor and Rictor, 
respectively. Silencing expression of either Raptor or Rictor resulted in downregulation of 
both VEGFR-2 and RGS4 mRNA (Fig. 7B). Moreover, both knock-down transfectants were 
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less invasive than control transfectants (Fig. 7C). As recently published work suggested 
inhibition of RGS4 expression by the PI3K/AKT/glycogen synthase kinase (GSK)-3 pathway 
(Hu et al., 2009), we also examined the option that RGS4 could be regulated through AKT 
upon its feedback activation at low CCI-779 concentrations (Fig. 7A). CCI-779 at 10 nmol/L 
abolished RGS4 expression, but did not alter the phosphorylation of GSK-3 at S9. GSK-
3is inactivated by phosphorylation through AKT kinase activity (Supplementary Fig. 3A). 
Conversely, dephosphorylation-mediated activation of GSK-3 promoted by the protein 
kinase C- inhibitor enzastaurin (Tabatabai et al., 2007) was not accompanied by an 
increase in mRNA or protein expression of RGS4 (Supplementary Fig. 3B). In summary, 
angiogenesis and invasion depending on signalling through VEGFR-2 and RGS4, 
respectively, are controlled through both mTOR complexes, mTORC1 and mTORC2, and 
regulated independent from AKT activity. 
 
CCI-779 inhibits glioma angiogenesis and invasion 
CCI-779- and CCI-779/RT-exposed tumours disclosed a weaker vascularisation pattern than 
control or RT-treated tumours as quantitatively assessed on grounds of CD31-specific 
immunoreactivity (Fig. 8A, top row, and Fig. 8B). Importantly, expression of invasion-
associated RGS4 was almost abolished in all CCI-779-treated tumours regardless of 
irradiation (Fig. 8A, bottom row). Immunoblot analysis was used in addition to verify that 
RGS4 was severely suppressed through CCI-779 (Fig. 8C). In addition to considerable 
control of tumour growth, the combined treatment regimen reduces angiogenesis and 
invasion even in a highly tumourigenic, supposedly less responsive PTEN wild-type tumour 
while adverse reactions potentially owed to the host immune system did not become evident. 
 
CCI-779 combined with radiotherapy or lomustine has unexpected clinical efficacy 
In 12 individual treatments of patients with highly recurrent glioblastomas at the Medical 
Center in Heidelberg, Germany, CCI-779 in combination with radiotherapy (n = 7) or 
lomustine (n = 5) resulted in objective tumour responses in three patients and a promising 
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progression-free survival interval of 4.8 months including 5 patients who even benefited 
following a VEGF-antagonizing regimen (Table 2). The value of these observations may 
even be greater when compared with lomustine monotherapy data in controlled trials (Wick 
et al., 2010). Whether these results translate into a clinically favourable outcome will be 
investigated in a current controlled phase II trial on CCI-779 in combination with radiotherapy 
as first-line treatment of glioblastoma (EudraCT number 2008-003003-31). 
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Discussion 
Inhibition of the adaptive-evasive response involving augmented tumour cell invasion or 
increased dissemination and distant metastasis is a logical step towards next generation 
antiangiogenic treatment. Here we report and molecularly define the combined administration 
of ionizing radiation together with mTOR inhibition exerts such a likewise control of 
angiogenesis and invasiveness in a highly vascularised and invasion-prone cancer type, 
glioblastoma. 
Given the strongly cytostatic and combined antiangiogenic/antiinvasive effects of CCI-779 as 
demonstrated in our study, why have mTOR-antagonizing regimens, whether applied as 
single-agent therapy or combined with EGFR inhibition produced disappointing results in 
clinical trials for recurrent glioblastoma? One explanation could be the switch from a 
proneural to a mesenchymal phenotype (Phillips et al., 2006) preventing anti-tumour effects 
of PI3K/AKT/mTOR targeting. Another reason proposed recently could be that mTOR-
antagonized glioma cells develop protection from hypoxia-induced cell death and might thus 
better tolerate the adverse conditions of the hypoxic microenvironment within unresectable 
tumour burdens frequently faced at recurrence (Ronellenfitsch et al., 2009). Hence, 
macroscopically complete tumour resection minimizing the occurrence of hypoxia could be a 
favourable predictive factor for the responsiveness towards mTOR inhibition. Third, dosing 
might be critical to prevent unwanted AKT activation. Finally, it is conceivable that mTOR-
antagonizing strategies could be insufficient when applied as monotherapies and only be 
reasonable when administered in combination with a cytotoxic regimen, e.g., radiation 
therapy or lomustine (Table 2), but too toxic if applied in combination with radiation and 
chemotherapy (Sarkaria et al., 2010). Our present data suggest that this might be the case 
as both ionizing radiation and CCI-779 clearly synergize in causing anti-glioma effects (Fig. 
1, 2). 
The observation that mTOR inhibition is antiangiogenic in an intracerebral tumour model is 
novel: In myeloma and breast cancer cell lines, mTOR inhibition inhibits VEGF release 
through inhibition of HIF-1 expression and transcriptional activation (Frost et al., 2004; Del 
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Bufalo et al., 2006). Our data demonstrate that mTOR inhibition suppresses VEGF 
production driven by both hypoxia and irradiation in glioma cells (Fig. 3A,B). Importantly, we 
propose that mTOR inhibition targets tumour angiogenesis by at least two distinct 
mechanisms both causing severe impairment of endothelial functions: a) indirectly, through 
transcriptional inhibition of VEGF release from glioma cells (Fig. 3A,B) and (b) directly, 
through transcriptional downregulation of VEGFR-2 on glioma (Fig. 5A,B) and endothelial 
cells (Fig. 5C). Like VEGFR-1, VEGFR-2 is primarily located on the vascular endothelium, 
but its expression has also been verified on neuronal, hematopoietic and cancer cells 
including glioma cells (Knizetova et al., 2008; Ivy et al., 2009). Notably, expression of both, 
VEGF and VEGFR-2, becomes induced as a consequence of ionizing radiation and is 
markedly counteracted in response to treatment with CCI-779 (Fig. 3A, 5A). 
When challenged in vivo using the orthotopic VM/Dk mouse glioma model, CCI-779 
significantly diminished intratumoural vascularisation as assessed by CD31-based semi-
automated vessel counting of syngeneic SMA-560 gliomas (Fig. 8A). In contrast, 
antiangiogenic activity was not described for another rapamycin analog, RAD001, in a 
glioblastoma orthotopic xenograft test panel (Yang et al., 2008). This discrepancy suggests 
that, given the specific microenvironment of the central nervous system (CNS), suppression 
of glioma angiogenesis through rapalogs may be unique to CCI-779 rather than a common 
rapalog class effect. 
Of the various strategies that have been designed to target VEGF/VEGFR signalling, there 
has been no such single-agent therapy that causes multilevel blockade of signal transduction 
at a time: The clinically most successful anti-VEGF agent, the monoclonal anti-VEGF 
antibody bevacizumab, as well as the VEGF trap, aflibercept, a soluble decoy receptor 
binding VEGF, both act at the ligand level. Other strategies are directed against VEGF (and 
additional other) receptors including small-molecule multikinase inhibitors, e.g., cediranib, 
sunitinib, sorafenib, vandetanib, vatalanib, or BIBF 1120, and monoclonal antibodies against 
VEGFR-1 and VEGFR-2 (Heath and Bicknell, 2009). Our findings indeed implicate that CCI-
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779 targets angiogenic processes by interfering with the VEGF/VEGFR-2 signalling axis both 
at the ligand and the receptor level, and might thus act more efficaciously. 
Most recent findings stemming from mouse models suggest a HIF-1-dependent mechanism 
based on the interaction between the stromal cell-derived factor-1 (SDF-1) and its receptor, 
CXCR4, that underlies the recruitment of bone marrow-derived cells (BMDC), primarily 
CD11b+ myelomonocytes, into glioblastomas in response to irradiation, restoring the 
radiation-damaged vasculature by vasculogenesis and thereby allowing the growth of 
surviving tumour cells (Kioi et al., 2010). Given its HIF-1-suppressing effect, CCI-779 might 
additionally interfere with this influx of BMDC into tumours and prevent the postirradiation 
development of a functional tumour vasculature, thus counteracting the unwanted 
angiogenesis-stimulating side effects of radiation therapy. It is therefore conceivable that 
CCI-779 impairs not only angiogenesis but also vasculogenesis, at least in gliomas. 
Both VEGF-antagonizing and VEGFR-2-directed strategies have been well documented to 
provoke an unwanted adaptive-evasive response in preclinical models as well as in clinical 
investigations (Casanovas et al., 2005; Paez-Ribes et al., 2009; Kunkel et al., 2001; Gomez-
Manzano et al., 2008) although a clinically relevant specific proinvasive property of 
bevacizumab is questioned by others (Wick et al., in press). We further demonstrate that 
mTOR inhibition not only disrupts VEGF/VEGFR-2 angiogenic signalling efficaciously but 
also suppresses glioma cell migration and invasion by virtue of downregulation of RGS4 that 
we functionally characterize as a potent driver molecule of glioma cell invasiveness (Fig. 6). 
RGS4 belongs to the superfamily of RGS proteins that comprises, in mammalian cells, more 
than 30 molecules being important regulatory components of signal transduction pathways 
initiated through heterotrimeric guanine nucleotide binding (G-)protein-coupled receptors 
(GPCR) (Bansal et al., 2007). RGS proteins are linked to the initiation and progression of 
cancer (Hurst and Hooks, 2009). They serve as strong regulatory molecules that act as 
GTPase-activating proteins and thus shorten the duration and reduce the magnitude of 
heterotrimeric GPCR signalling that underlies a wide variety of cellular processes including 
cell motility (De Vries et al., 2000; Cotton and Claing, 2009). RGS4 is such a molecule that 
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has previously been ascribed a role in controlling breast cancer cell invasiveness by 
disrupting Ras-related C3 botulinum toxin substrate (Rac)1-dependent lamellipodia 
formation. Down-regulation of RGS4 by proteasome degradation resulted in a metastatic 
phenotype (Xie et al., 2009). Here, we show CCI-779 specifically reduces RGS4 expression 
(Fig. 6A,B) and suppresses RGS4-induced invasiveness of human glioma cells in vitro and in 
vivo (Fig. 6C, 8A). RGS4 has been reported to be enriched and widely expressed in the 
mammalian brain (Erdely et al., 2004; Ebert et al., 2006a; Ebert et al., 2006b), making it 
particularly relevant for brain tumour research. Furthermore, changes in RGS4 expression or 
activity have been linked to other major CNS disorders, including Parkinson’s disease (Ding 
et al., 2006), schizophrenia (Levitt et al., 2006), and drug addiction (Hooks et al., 2008). 
Therefore, RGS4 has been increasingly recognized as a promising therapeutic target for 
inhibition, and specific drug development is currently under way (Blazer et al., 2010). 
Our findings showing that CCI-779 elicits combined antiangiogenic and antiinvasive effects 
stimulated our interest in underlying signalling mechanisms. Recently, mTORC2 has been 
recognized as an emerging player in cancer and a promising candidate target for inhibition. 
Consequently, a number of (FKBP12-independent) adenosine triphosphate (ATP)-
competitive mTOR kinase inhibitors, e.g., Torin1, PP242, PP30, have been developed that 
target both mTOR complexes at similarly low IC50 values, and considerations to develop 
mTORC2-specific inhibitors are currently under way (Guertin and Sabatini, 2009). In contrast 
to rapamycin and its analogs that have a well-established safety profile, it remains to be 
proven whether this new class of mTOR ATP-competitive inhibitors will have an impact in 
clinical use. Meanwhile, our data implicate that, in glioblastoma and potentially also in other 
neoplastic cells, mTORC2 is targetable by the rapalog inhibitor CCI-779 at clinically relevant 
concentrations: In PTEN-mutated glioma cells, CCI-779 applied within the nanomolar range 
partially suppressed mTORC1 activity resulting in decreased expression of VEGF (Fig. 
3A,B), VEGFR-2 (Fig. 5) and RGS4 (Fig. 6A,B), paralleled by impaired angiogenesis and 
invasiveness (Fig. 8A). As a consequence, a feedback loop through mTORC2 signalling 
activates AKT by phosphorylation at the critical regulatory site S473 required for maximal AKT 
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kinase activity leading to adverse effects such as increased cell survival and invasiveness 
(Fig. 7A, 9A). CCI-779 applied in the micromolar range overcomes the protective effect of a 
PTEN wild-type status, inhibits both mTOR complexes at a time and thus prevents the 
induction of resistance through feedback activation of AKT by mTORC2 (Fig. 7B). Our data 
suggest that PTEN is only of limited value in predicting the sensitivity of glioma cells to 
mTOR inhibition with CCI-779. In addition, the concerted inhibition of both mTOR complexes 
results in a more efficacious suppression of VEGFR-2 and RGS4 leading to a tighter control 
of angiogenesis and invasiveness (Fig. 7C, 8A, 9B). In line with recent propositions favouring 
a dual or even sole inhibition of mTORC2 (Guertin and Sabatini, 2009), we conclude that 
combined inhibition of mTORC1 and mTORC2 is beneficial and can be attained, at least in 
glioma, through CCI-779 at levels achieved in the clinic at approximately 50-75 mg applied 
intravenously.  
Taken together, CCI-779 holds the proangiogenic and proinvasive consequences of 
irradiation in check. In this regard, inhibition of mTOR with CCI-779 for the treatment of 
glioblastoma may be most successful in the setting of primary treatment when 
macroscopically complete resections are more likely doable than at relapse, and radiation 
therapy is subsequently administered. 
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Table legends 
Table 1 
PTEN status of glioma cells and response to CCI-779.  
All glioma cells were analyzed for PTEN cDNA sequence, PTEN promoter methylation, 
PTEN protein expression, and phosphorylation of AKT at T308 and S473. Paraffin-embedded 
tumour specimens parental of the GIC cultures were assessed by PTEN-specific 
immunohistochemistry. The IC50 of CCI-779 was determined by the trypan blue exclusion 
method. IC50, half maximal inhibitory concentration 50%; IHC, immunohistochemistry; M, 
methylated; mut, mutated; U, unmethylated; WB, Western blot; wt, wild-type. See also 
Supplementary Fig. 2 for details. 
 
Table 2 
Clinical outcome of CCI-779-based individual treatments for recurrent glioblastoma. 
Baseline characteristics and outcome data of 12 individual treatments of highly recurrent 
glioblastomas using Torisel® in combination with radiotherapy (n = 7) or lomustine (n = 5). 
Data are compared with results from a phase III clinical trial that contained lomustine 
monotherapy in the control arm as treatment for first and second recurrence of glioblastoma 
(Wick et al., 2010). PFS, progression-free survival; OS, overall survival. 
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Figure legends 
Figure 1 
mTOR inhibition disrupts angiogenesis and invasion and prolongs survival in a 
syngeneic mouse glioma model. (A) Immunoblot analysis of RPS6 phosphorylation (P-
RPS6) in PTEN wild-type SMA-560 cells following CCI-779 treatment. (B) MRI-monitored (n 
= 3) orthotopic growth analysis (top row) of SMA-560 glioma experimental groups (each n = 
14) as detailed in Materials and Methods: (i) Control, (ii) RT, (iii) CCI-779, and (iv) CCI-
779/RT. MRI-scanned mice were sacrificed for immunohistochemistry on day 20: H&E, 
middle row; scale bars, 2 mm; P-RPS6, bottom row; scale bars, 20 µm. (C) For survival 
analysis, eleven animals in each group as in (B) were observed in daily intervals and killed at 
the onset of neurological symptoms. Survival data are plotted by the Kaplan-Meier method 
and analyzed by the log-rank test (n = 11 per treatment group, *p < 0.05). 
 
Figure 2 
Irradiation-combined mTOR inhibition causes cytostatic anti-glioma effects. (A) 
Immunoblot analyses for RPS6 phosphorylation (P-RPS6) of lysates prepared from CCI-779-
treated glioma cells. eIF4E served as a loading control. PTEN wild-type (PTEN wt) and 
PTEN-mutated (PTEN mut) glioma cells were discriminated by sequence analysis of PTEN 
cDNA. (B) Cell cycle analysis of DAPI-stained LN-308 glioma cells following treatment as 
indicated (mean ± SD, n = 3, *p < 0.05). (C) Clonogenic survival of LN-308 cells following 
treatment as indicated (mean ± SD, n = 3, *p < 0.05 relative to unirradiated, vehicle-treated 
control condition set as 100%). (D) Sphere formation capacity of T325 GIC. Top: data are 
expressed as percentages of sphere number and sphere size, respectively, relative to the 
unirradiated, DMSO-treated control condition set as 100% (mean ± SD, n = 3, *p < 0.05). 
Bottom: Representative T325 GIC-derived glioma spheres are depicted (scale bar, 200 µm). 
(E) Flow cytometry-based analysis of autophagy in LN-308 cells. Data are expressed as 
percentages of acridine orange-positive cells, and percentage of five was set as the 
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autophagic baseline level in vehicle-treated control cells (mean ± SD, n = 3 for each 
condition, *p < 0.05). See also Supplementary Fig. 1. 
 
Figure 3 
Irradiation-enhanced mTOR inhibition exerts antiangiogenic effects in vitro. (A and B) 
CCI-779 was assessed for its effect on VEGF release promoted by ionizing radiation (A) and 
hypoxia (B). (A) LN-308 glioma cells were pretreated as indicated and irradiated (RT) or not 
after 24 h. (B) LN-308 glioma cells cultured at 21% oxygen or at 1% oxygen were exposed to 
DMSO or CCI-779. Top: VEGF concentrations in conditioned supernatants collected from 
cells in A and B 48 h thereafter were quantified by ELISA (mean ± SD, n = 3, *p < 0.05). 
Bottom: Protein lysates prepared from the same cells in (A) and (B) were analyzed for 
expression of HIF-1 and -tubulin that served as a loading control. (C and D) Viability of 
HUVEC (C) and brain-derived hCMEC/D3 (D) in response to treatment with CCI-779 and 
irradiation. Responding more sensitively towards radiation, hCMEC/D3 were treated at lower 
radiation doses than HUVEC. Data are expressed relative to the vehicle-treated control 
condition set to 100% (mean ± SD, n = 3, *p < 0.05). (E) Left: VEGF-induced sprouting of 
HUVEC spheroids in response to CCI-779 (mean ± SD, n = 3, *p < 0.05). VEGF was applied 
at 25 ng/mL. Right panel: representative sprouting HUVEC spheroids are depicted (scale 
bars, 100 µm). 
 
Figure 4 
mTOR inhibition is antiinvasive and counteracts the proinvasive effect of sublethal 
irradiation irrespective of PTEN. (A) PTEN wild-type (PTEN wt) and PTEN-mutated (PTEN 
mut) glioma cell lines or (B) pretreated LNT-229 cells were assayed in matrigel invasion 
chambers. Data are expressed as percentages of invaded cells relative to the respective 
non-irradiated vehicle control. (C and D) Preformed spheroids derived from PTEN wild-type 
LNT-229 cells (C) and T269 GIC (D) treated as indicated were assayed for invasion into a 3-
dimensional protein gel matrix. Data are expressed as percentages of the mean migrated 
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distance relative to the initial radius of each individual spheroid at 0 h (n = 3, *p < 0.05). (D) 
Right: representative T269 GIC spheroids at 72 h are depicted (scale bars, 100 µm). 
 
Figure 5 
mTOR inhibition downregulates VEGFR-2 on glioma and endothelial cells. (A) 
Microarray validation of CCI-779-mediated downregulation of VEGFR-2 mRNA in LN-308 
cells by qRT-PCR (mean ± SD, n = 3, *p < 0.05). (B) Immunoblot analysis of VEGFR-2 
protein expression in PTEN wild-type (PTEN wt) and PTEN-mutated (PTEN mut) glioma 
cells. (C) Top: qRT-PCR analysis of VEGFR-2 mRNA expression in HUVEC treated as 
indicated. Bottom: immunoblot analysis of VEGFR-2 protein expression in HUVEC following 
treatment as indicated for top panel (mean ± SD, n = 3, *p < 0.05). GAPDH served as a 
loading control in B and C, bottom panel. 
 
Figure 6 
RGS4 is a novel invasion-associated target of mTOR inhibition. (A) Microarray validation 
of CCI-779-mediated downregulation of RGS4 mRNA in LN-308 cells by qRT-PCR (mean ± 
SD, n = 3, *p < 0.05). (B) Immunoblot analysis of RGS4 protein expression in PTEN wild-
type (PTEN wt) and PTEN-mutated (PTEN mut) glioma cells. GAPDH served as a loading 
control. (C) Comparative analysis of RGS4 mRNA expression by qRT-PCR and matrigel 
invasion of LN-308 glioma cells upon siRNA-mediated knock-down (siRGS4, left) or stable 
overexpression of RGS4 (pCR3.0-RGS4, middle), and upon treatment with CCI-779 (right). 
QRT-PCR data are expressed as fold changes relative to respective control-transfected 
cells, i.e. siScramble or pCR3.0, set as 1 each (see left y-axis; mean ± SD, n = 3, *p < 0.05). 
Invasion data are expressed as percentages of invaded cells relative to the same controls 
set as 100% each (see right y-axis; mean ± SD, n = 3, *p < 0.05). (D) Immunoblot of control 
(pCR3.0) and stably RGS4-overexpressing (pCR3.0-RGS4) LN-308 cells. Actin served as a 
loading control. (E) Differences in cell viability between pCR3.0- and pCR3.0-RGS4-
transfected LN-308 cells as potential bias of invasion results were excluded by crystal violet 
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staining. Data are expressed as percentages of viable pCR3.0-RGS4-transfected cells 
relative to empty vector-transfected cells set to 100% (mean ± SD, n = 3). (F) Representative 
T2-weighted MRI on day 48 after orthotopic implantation of pCR3.0- (left) and pCR3.0-
RGS4-transfected (middle) human LN-308 glioma cells. Right: comparative T2-based 
volumetry of pCR3.0- and pCR3.0-RGS4-transfected LN-308 tumour lesions (mean ± SD, n 
= 4 animals per group, *p < 0.05). (G) Histological analysis of coronally cryosectioned and 
hematoxylin/eosin (H&E)-stained mouse brains harbouring RGS4-overexpressing LN-308 
gliomas (right) or control gliomas (left) (scale bars, 1 mm). 
 
Figure 7 
High-dosed CCI-779 prevents AKT activation and inhibits mTORC1 and mTORC2 both 
controlling expression of VEGFR-2 and RGS4-dependent glioma cell invasion. (A) 
Immunoblot analyses of RGS4 and VEGFR-2 expression and phosphorylation of mTORS2481, 
AKTS473 and RPS6 in LN-308 glioma cells treated with CCI-779 at 10 nmol/L or 10 µmol/L. 
eIF4E and GAPDH served as loading controls. (B) QRT-PCR-based analysis of VEGFR-2 
and RGS4 mRNA expression in Raptor-silenced (left) and Rictor-silenced (right) LN-308 
glioma cells. Non-targeting scramble siRNA (siScramble) served as a control. Data are 
expressed as fold changes of each transcript relative to its expression in DMSO-treated 
siScramble-transfected cells set as 1 (mean ± SD, n = 3, *p < 0.05). (C) Left: Matrigel 
invasion data of Raptor- and Rictor-silenced LN-308 glioma cells are expressed as 
percentages of invaded cells relative to siScramble-transfected control cells set to 100% 
(mean ± SD, n = 3, *p < 0.05). Right: representative Boyden chamber membranes as 
quantified in the left panel (scale bars, 100 µm). See also Supplementary Fig. 3. 
 
Figure 8 
mTOR inhibition disrupts angiogenesis and invasion in a syngeneic mouse glioma 
model. (A) Comparative immunohistochemical analysis of SMA-560 gliomas in each 
treatment group (as in Fig. 1 B): CD31, top row; scale bars, 100 µm; RGS4, bottom row; 
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scale bars, 50 µm. (B) Mean vascularisation of SMA-560 gliomas in each treatment group 
was assessed by automated quantification of the total CD31-positive vessel area depicted in 
(A), top row (mean ± SD, n = 3 per treatment group, *p < 0.05). (C) Immunoblot analysis of 
RGS4 in CCI-779-treated SMA-560 cells in vitro. GAPDH served as a loading control. 
 
Figure 9 
mTORC1 and mTORC2 signals direct angiogenesis and invasion in glioma and are 
both inhibited by high-dosed CCI-779. Angiogenic and invasive signalling through mTOR 
in response to low (A) and high (B) concentrations of CCI-779. mTORC1 comprises five 
components: mTOR, which is the catalytic subunit of the complex; regulatory-associated 
protein of mTOR (Raptor); mammalian lethal with Sec13 protein 8 (mLST8); proline-rich AKT 
substrate 40 kDa (PRAS40); and DEP-domain-containing mTOR-interacting protein (Deptor). 
mTORC2 consists of six different proteins, several of which are common to mTORC1 and 
mTORC2: mTOR; rapamycin-insensitive companion of mTOR (Rictor); mammalian stress-
activated protein kinase interacting protein (mSIN1); protein observed with Rictor-1 (Protor-
1); mLST8; and Deptor. 
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Tables 
Table 1. PTEN status of glioma cells and response to CCI-779. 
 -------------------------------------- PTEN -------------------------------------- ------- AKT activation -------
 
 
 
Cells 
 
 
cDNA 
 
Promoter 
 
Protein (WB) 
 
Protein (IHC) 
 
P-AKTT308 
 
P-AKTS473 
 
IC50 (CCI-779) 
 
 
LNT-2291 
 
wt M + N/A - - 7.9 µmol/L 
 
LN-4281 
 
 
wt 
 
U 
 
 
+ 
 
 
N/A 
 
 
+ 
 
 
- 
 
 
9.7 µmol/L 
 
 
LN-181 
 
 
wt 
 
 
M 
 
 
+ 
 
 
N/A 
 
 
- 
 
- 
 
0.8 nmol/L 
 
 
LN-3081 
 
 
mut3 
 
 
M 
 
 
- 
 
 
N/A 
 
 
+ 
 
 
+ 
 
 
0.7 nmol/L 
 
 
T98G1 
 
 
mut4 
 
 
U 
 
 
+ 
 
 
N/A 
 
 
+ 
 
 
- 
 
 
0.6 nmol/L 
 
 
U87MG1 
 
 
mut5 
 
 
U 
 
 
- 
 
 
N/A 
 
 
+ 
 
 
+ 
 
 
0.8 nmol/L 
 
 
SMA-5602 
 
 
wt 
 
 
U 
 
 
+ 
 
 
N/A 
 
 
+ 
 
 
- 
 
 
3.6 µmol/L 
 
 
T2691 
 
 
wt 
 
 
U 
 
 
+ 
 
 
+ 
 
 
+ 
 
 
+ 
 
 
5.2 µmol/L 
 
 
T3251 
 
 
mut6 
 
 
U 
 
 
+ 
 
 
- 
 
 
- 
 
 
+ 
 
 
3.2 µmol/L 
 
 
1 Human 
2 Murine 
3 Truncating frameshift mutation through d165/212 (corresponds to a deletion of exon 6) and subsequent stop codon at 173 
4 In-frame point mutation L42R 
5 In-frame point mutation R55S plus d56/70 (corresponds to an in-frame deletion of exon 3) 
6 In-frame point mutation M134I 
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Table 2. Clinical outcome of CCI-779-based individual treatments for recurrent     
glioblastoma. 
 
Characteristic CCI-779 (n = 12) Lomustine1 (n = 92) 
Median age (range), years 49 (28-73) 55 (18-76) 
Sex (female/male), n 3/9 36/56 
Median Karnofsky Performance Status 
(range), % 
80 (50-100) 80 (70-100) 
Median time from diagnosis (range), months 14.3 (8.8-42) 12.1 (4.4-92)  
Steroid use at start of treatment, %  67  52 
First/second/more relapses, n 0/2/10 71/21/0 
Concurrent therapy, n  
Radiotherapy 
Lomustine          
 
7 
5 
 
none 
 
Best response (complete or partial  
response/stable disaese)2, n 
3/9 4/33 
Median PFS (range), months 4.8 (1.2-14.4) 1.6 (1.5-2.8) 
PFS rate at 6 months (range), % 34 (22-48) 19 (10.1-27.8) 
OS after current treatment (range), months 6.5 (5.7-9) 7.1 (6-8.8) 
 
1Data from phase III clinical trial that contained lomustine in the control arm as treatment for 
first and second recurrence of glioblastoma according to Wick et al., 2010.  
2according to (Smyth et al., 2004). 
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1. Supplementary figure legends 
Supplementary Figure 1 (related to Figure 2) 
(A) Immunoblot analysis of RPS6 phosphorylation (P-RPS6) in lysates of LN-308 glioma 
cells prepared 48 h after combined pretreatment with DMSO or CCI-779 (1 nmol/L and 10 
nmol/L) for 24 h and subsequent irradiation (0 Gy, 0.5 Gy, 2 Gy, and 4 Gy). Eukaryotic 
translation initiation factor 4E (eIF4E) served as a loading control. (B) Flow cytometry-based 
analysis of apoptosis in AnxV-FITC/DAPI-stained LN-308 glioma cells treated with DMSO, 
irradiation at 8 Gy or CCI-779, as indicated. Data are expressed as percentages of apoptotic 
cells relative to the respective total cell population set to 100% (mean ± SD, n = 3; *p < 0.05 
compared with the unirradiated DMSO control, left). 
 
Supplementary Figure 2 (related to Table 1) 
The PTEN status is of limited predictive value regarding the growth sensitivity of 
glioma cells to mTOR inhibition. (A) Methylation analysis of the PTEN promoter region by 
methylation-specific PCR (MSP) of bisulfite-converted genomic DNA derived from six naïve 
human glioma cell lines (LNT-229, LN-428, LN-18, LN-308, T98G, and U87MG), the murine 
astrocytoma cell line SMA-560, and primary human GIC cultures (T269 and T325). PCR 
products were separated on a 3% agarose gel. PCR bands generated with primers used to 
detect methylated DNA sequences (M) indicate a methylated PTEN promoter region; PCR 
bands generated with primers used to detect unmethylated DNA sequences (U) indicate an 
unmethylated PTEN promoter region. H2O as well as bisulfite-treated hypermethylated 
(meth) and unmethylated (unmeth) genomic DNA probes served as controls. bp, base pairs. 
(B) Immunoblot analysis of PTEN expression and phosphorylation of AKT at T308 (P-AKTT308) 
and at S473 (P-AKTS473) in lysates of glioma cells as specified in A. Total AKT served as a 
loading control. (C) PTEN immunohistochemistry of paraffin-embedded T269 and T325 
human glioblastoma specimens. The PTEN wild-type tumor T269 (left) shows overall PTEN-
specific immunoreactivity whereas in the PTEN-mutated specimen T325 (right), only PTEN 
wild-type vessels become immunoreactive. Both tumor specimen were used to derive the 
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two primary GIC cultures T269 and T325 thereof. Magnification, 200x. (D) Viability of PTEN 
wild-type (PTEN wt; left) and PTEN-mutated (PTEN mut; middle) glioma cell lines as well as 
of the two primary human GIC cultures T269 (PTEN wt) and T325 (PTEN mut) (right) in 
response to CCI-779 at indicated concentrations as assessed by the trypan blue exclusion 
method. Data are expressed as percentages of trypan blue-unstained cells relative to viable 
DMSO-treated cells set to 100% (mean ± SD, n = 3). 
 
Supplementary Figure 3 (related to Figure 7) 
Downregulation of RGS4 mediated by mTOR inhibition is independent from GSK-3 
signaling. (A) Immunoblot analysis of RGS4 expression and GSK-3 phosphorylation at S9 
(P-GSK-3S9) in lysates of LN-308 glioma cells treated with DMSO or CCI-779 (10 nmol/L) 
for 48 h. Total GSK-3 served as a loading control. (B) Left: Relative RGS4 mRNA 
expression as quantified by qRT-PCR in LN-308 cells treated with the protein kinase C- 
inhibitor enzastaurin (ENZA, 5 µmol/L) or DMSO as a vehicle control for 24 h (mean ± SD, n 
= 3; n.s., not significant). Right: Immunoblot analysis of RGS4 expression and GSK-3 
phosphorylation at S9 (P-GSK-3S9) in lysates of LN-308 glioma cells treated with DMSO or 
ENZA (5 µmol/L) for 24 h. Total GSK-3 served as a loading control. 
 4
2. Supplementary tables 
 
 
Supplementary Table 1. List of PCR primers. 
Target Forward primer 
 
Reverse primer Company 
Genomic PCR: 
Human PTEN, 
product: 1497 bp 
5'-GCATCAGCTACCGCCAAGTC-3'  5'-GTGTCAAAACCCTGTGGATG-3'  
Sigma-Aldrich, Taufkirchen, 
Germany Murine PTEN,  
product: 1514 bp 
5'-GCATCAGCGACCGCCAAGTC-3'  5'-GTGTCAAAACCCTGTGGATG-3' 
qRT-PCR: 
RGS-4 5'-GCTTCTTGCTTGAGGAGTGC-3' 5'-GGGAAGAATTGTGTTCACAGG-3'  
Sigma-Aldrich, Taufkirchen, 
Germany 
 
VEGFR-2 5'-GCGTGGTCAGGCAGCTCACA-3'  5'-GGGGATTCCCAGATGCCGTGC-3' 
Raptor 5'-TAGTTTTGTGCCTGAATGTTGGT-3' 5'-GAGCTTTCTGAGGACCCATCG-3' 
Rictor 5'-CGAGTACGAGGGCGGAATG-3'  5'-TCAGATGGCCTAGCTTTCTCATA-3' 
Methylation-specific PCR1: 
Methylated  
human PTEN,  
product: 178 bp 
5'-GTTTGGGGATTTTTTTTTCGC-3'  5'-AACCCTTCCTACGCCGCG-3'  
 
 
 
 
Eurofins MWG Operon, 
Ebersberg, Germany 
 
Unmethylated 
human PTEN,  
product: 186 bp 
5'-TATTAGTTTGGGGATTTTTTTTTTGT-3'  5'-CCCAACCCTTCCTACACCACA-3' 
Methylated  
murine PTEN, 
product: 177 bp 
5'-TTGGGGATTTTTCGCGTTAGC-3' 5'-CCCTCTCTTACCGAATCG-3' 
Unmethylated 
murine PTEN, 
product: 185 bp 
5'-ATAGTTTGGGGATTTTTTGTGTTAGT-3' 5'-AACCCCTCTCTTACCAAATCA-3' 
 
1Denaturation at 95°C for 10 min; 38 PCR cycles at: denaturation, 94°C for 30 s; annealing, 55°C for 60 s; extension, 72°C for 55 s; final 
extension at 72°C for 10 min. 
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Supplementary Table 2. List of antibodies. 
 
 
Target Source Concentration / 
Dilution 
Company 2nd 
Antibody 
Immunoblotting: 
Pathscan Multiplex 
Cocktail I  
(Phospho-AKTS473, 
Phospho-RPS6, 
eIF4E) 
 
 
rabbit 
 
 
1:200 
 
 
 
 
 
 
 
 
Cell Signaling, 
Danvers, MA, USA 
 
+ 
 
RPS6 mouse  
 
 
 
1:1000 
# 
Phospho-mTORS2481  
  
 
  rabbit 
 
 
 
+ 
VEGFR-2  
Phospho-GSK-3S9 
GSK-3 
Phospho-AKTT308 
Phospho-AKTS473 
AKT 
PTEN rabbit 0.1 µg/mL  
R&D Systems, 
Minneapolis, MN, USA 
 
+ 
RGS4 (C17) goat 1 µg/mL Santa Cruz 
Biotechnologies, 
Santa Cruz, CA, USA 
 
* 
HIF-1 mouse 2 µg/mL Novus Biologicals, 
Littleton, CO, USA 
# 
GAPDH  
   goat 
 
1:1000 
 
Abcam, Cambridge,  
UK 
 
* 
-Actin   Santa Cruz 
Biotechnologies, 
Santa Cruz, CA, USA 
 
-Tubulin mouse 1:5000 Sigma-Aldrich, 
Taufkirchen, Germany 
# 
*Goat  
donkey 
 
1:2000 
 
 
 
                     GE Healthcare, UK +
Rabbit 
#
Mouse  sheep 
Immunohistochemistry: 
PTEN   rabbit 1:200 R&D Systems, Lille, 
France 
Ultraview Red 
Detection Kit; 
Ventana, 
France 
Phospho-RPS6 rabbit 1:200 Cell Signaling + 
+
rabbit-biotinylated    goat 1:200 
Vector Laboratories, Burlingame, CA, 
USA 
Vectastain Elite avidin-biotin complex kit (Vector Laboratories) with cobalt chloride-
intensified 3,3'-diaminobenzidine (DAB) as chromagen (Sigma-Aldrich) 
CD31 rat 10 µg/mL BD Bioscience, 
Heidelberg, Germany ° 
°rat Alexa Fluor 546  goat          1:500 Invitrogen, Karlsruhe, Germany 
RGS4 (N-16) goat 4 µg/mL Santa Cruz 
Biotechnologies        ^ 
^goat  Alexa Fluor 488 donkey          1:500 Invitrogen 
4,6-diamidino-2-phenylindol (DAPI; Vectashield Mounting Medium with DAPI, H1200, 
Vector Laboratories) counterstaining
Flow cytometry: 
BrdU-FITC mouse 1:50 BD Bioscience, Heidelberg, Germany
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